| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453712 | Lung Cancer | 2018 | 5 Pages |
Abstract
In this large series of resected NSCLC, ALK rearrangements were associated with a trend toward inferior disease outcomes compared to other clinically relevant genomic subsets. These data support the need for clinical trials evaluating use of ALK inhibitors among ALK-positive patients with localized or locally-advanced disease.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jamie E. Chaft, Ibiayi Dagogo-Jack, Fernando C. Santini, Juliana Eng, Beow Y. Yeap, Benjamin Izar, Emily Chin, David R. Jones, Mark G. Kris, Alice T. Shaw, Justin F. Gainor,